Home > Journals > Minerva Biotechnology and Biomolecular Research > Past Issues > Minerva Biotechnology and Biomolecular Research 2021 June;33(2) > Minerva Biotechnology and Biomolecular Research 2021 June;33(2):65-75

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

REVIEW  BIOTECHNOLOGICAL AND PHARMACOLOGICAL DEVELOPMENTS IN THE MODIFICATION OF CHRONIC INFLAMMATION-INDUCED DISEASES Freefree

Minerva Biotechnology and Biomolecular Research 2021 June;33(2):65-75

DOI: 10.23736/S2724-542X.21.02766-X

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

Vitamin D in the prevention and treatment of type-2 diabetes and associated diseases: a critical view during COVID-19 time

Tetyana FALALYEYEVA 1 , Iuliia KOMISARENKO 2, Andrii YANCHYSHYN 3, Oleksandr KOVALCHUK 1, 3, Yuliia LOZKO 3, Olena TSYRYUK 1, Sharmila FAGOONEE 4, Nazarii KOBYLIAK 2, 5

1 Educational and Scientific Center Institute of Biology and Medicine, Taras Shevchenko National University of Kyiv, Kyiv, Ukraine; 2 Department of Endocrinology, Bogomolets National Medical University, Kyiv, Ukraine; 3 Department of Descriptive and Clinical Anatomy, Bogomolets National Medical University, Kyiv, Ukraine; 4 Institute of Biostructures and Bioimaging (CNR) c/o Molecular Biotechnology Center, Turin, Italy; 5 Laboratory of Pathology CSD Health Care, Kyiv, Ukraine



Vitamin D deficiency has been recognized as a pandemic with many negative health consequences in many countries. Today the mechanisms of anti-inflammatory and hepatoprotective action of vitamin D3 (cholecalciferol) and in general the scientific justification for its effective use in the clinic of type-2 diabetes (T2D) is actively studied in the scientific literature. We performed a review evaluating, that the treatment with vitamin D3 may increase the chances for successful convalescence: reduction of inflammation and hepatic steatosis; an increase of glycemic control and insulin sensitivity. The above-mentioned issue necessitates a deep and comprehensive study of an important scientific problem, which is the need for clinical justification of the effectiveness of vitamin D3 for the prevention and correction of metabolic disorders and structural and functional changes in the liver in T2D.


KEY WORDS: Vitamin D; Diabetes mellitus, type 2; Non-alcoholic fatty liver disease

top of page